Panavance Therapeutics

Panavance Therapeutics Inc. is a clinical-stage pharmaceutical company established in 2021 by Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie, to advance the development of GP-2250, a novel oncology therapy aimed at enhancing the effectiveness of cancer treatments and improving the quality of life for patients undergoing cancer treatment. With its highly capable team and robust academic and industry partnerships, Panavance is pursuing an aggressive program to bring GP-2250 to patients worldwide. To date, our therapy has demonstrated substantial efficacy and safety across a broad range of preclinical studies, with early clinical results showing promise. Panavance has developed a clear pathway for registering GP-2250 in the United States for the treatment of pancreatic cancer.